Voyageur Pharmaceuticals Ltd. (VYYRF)
| Market Cap | 19.74M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -1.52M |
| Shares Out | n/a |
| EPS (ttm) | -0.01 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,000 |
| Average Volume | 31,125 |
| Open | 0.1250 |
| Previous Close | 0.1250 |
| Day's Range | 0.1000 - 0.1250 |
| 52-Week Range | 0.0020 - 0.2500 |
| Beta | 0.44 |
| RSI | 44.42 |
| Earnings Date | Apr 25, 2025 |
About Voyageur Pharmaceuticals
Voyageur Pharmaceuticals Ltd., together with its subsidiaries, engages in acquiring, exploring, and developing raw materials for pharmaceutical products in the United States of America, the province of British Columbia, Canada, and the state of Utah. It develops barium and iodine-based APIs. The company offers Smooth HD, Smooth X, Smooth LD, Vision HD, Vision LD, V-Gas, and other products. Voyageur Pharmaceuticals Ltd. was formerly known as Voyageur Minerals Ltd. and changed its name to Voyageur Pharmaceuticals Ltd. in December 2019. The compan... [Read more]
Full Company ProfileNews
Voyageur Pharmaceuticals Announces Appointment of Ethan Mohan as Executive Vice President
Calgary, Alberta, Canada – May 12, 2025 – TheNewswire - Voyageur Pharmaceuticals Ltd. ( TSX.V:VM) ( OTC Pink:VYYRF) (" Voyageur " or the " Company ") a radiology contrast media company focused on ve...
Voyageur Pharmaceuticals Announces Changes to Board of Directors and DSU Grant
FOR IMMEDIATE RELEASE Ralph Hesje Retires as Chairman
Voyageur Pharmaceuticals Grants Deferred Share Units
Calgary, Canada – TheNewswire – April 7, 2025 - Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (OTC: VYYRF) ("Voyageur" or the "Corporation"), a provider of innovative medical imaging solutions, announces ...
Voyageur Completes Human Testing of Barium Contrast Products and Prepares for Canadian Market Launch
Calgary, Alberta, Canada – April 1, 2025 – TheNewswire - Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (OTC Pink:VYYRF) (" Voyageur " or the " Company ") is pleased to announce the successful completion of...
Voyageur Pharmaceuticals Advances Frances Creek Project, Paving the Way for a Secure, Vertically Integrated Barium Contrast Product Line
Calgary, Alberta, Canada – March 4, 2025 – TheNewswire - Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (OTC Pink:VYYRF) (“ Voyageur ” or the “ Company ”) is pleased to announce the commencement of the Fran...
Voyageur Clarifies Terms of Previously Announced Agreement
Calgary, Alberta--(Newsfile Corp. - March 3, 2025) - Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC Pink: VYYRF) ("Voyageur" or the "Company") wishes to clarify the terms of a distribution and wholesal...
Voyageur Pharmaceuticals Grants Deferred Share Units
Calgary, Canada – TheNewswire – February 24, 2025 - Voyageur Pharmaceuticals Ltd. (TSX.V : VM) (OTC: VYYRF) ("Voyageur" or the "Corporation"), a provider of innovative medical imaging solutions, anno...
Voyageur Advances MRI Drug Development Using Next Generation Endohedral Fullerenes
Calgary, Alberta, Canada – February 18, 2025 – TheNewswire - Voyageur Pharmaceuticals Ltd. ( TSX.V:VM) (OTC Pink:VYYRF) ("Voyageur" or the "Company") is pleased to announce the launch of its next gen...
Voyageur Receives $600K Grant from Alberta Innovates for Product Development
Voyageur receives $600,000 in funding through Alberta Innovates AICE-Market Access Program
Voyageur Announces Proposed Private Placement
Calgary, Alberta--(Newsfile Corp. - October 17, 2024) - Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC Pink: VYYRF) ("Voyageur" or the "Corporation"), is pleased to announce a proposed non-brokered pri...
Voyageur Pharmaceuticals Grants Stock Options
Calgary, Alberta--(Newsfile Corp. - September 25, 2024) - Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC Pink: VYYRF) ("Voyageur" or the "Company") announces that it has granted an aggregate of 600,000...
Voyageur Pharmaceuticals Ltd. Announces Equity Incentive Compensation
Calgary, Alberta--(Newsfile Corp. - December 2, 2022) - Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC Pink: VYYRF) (the "Company" or "Voyageur") announces that it has issued 125,322 Deferred Share Uni...
Voyageur Pharmaceuticals Ltd. Issuance of 5th Product License for MultiXThick Radiographic Barium Contrast
Voyageur Pharmaceuticals is moving forward with FDA device registrations for the US market. Voyageur Pharmaceuticals is moving forward with FDA device registrations for the US market.
Voyageur Pharmaceuticals Ltd. Issued 4th Health Canada License For Radiographic Barium Contrast Product
Voyageur is moving forward with its business plan of becoming the only fully-integrated company in the radiographic contrast medical field Voyageur is moving forward with its business plan of becoming...